High Incidence and Clinical Course of Aggressive Skin Cancer in Heart Transplant Patients: A Single-Center Study

Adamson, Robert; Obispo, E.; Dychter, Samuel S.; Dembitsky, Walter P.; Moreno-Cabral, Ricardo J.; Jaski, Brian E.; Gordon, John B.; Hoagland, P.; Moore, Kathleen A.; King, Joan M.; Andrews, John S.; Rich, Mike; Daily, Pat O.

doi:10.1016/s0041-1345(98)00178-x

Cited by 74 publications

(57 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[1][2][3][4] In addition to occurring more often, the cutaneous malignancies that occur in these patients tend to have a more aggressive clinical course. Skin cancers in organ transplant recipients have a greater tendency to metastasize distantly and are associated with higher mortality than skin cancer in the general population.…”

mentioning

confidence: 99%

Defining the Clinical Course of Metastatic Skin Cancer in Organ Transplant Recipients

Martinez

Otley²,

Stasko³

et al. 2003

Arch Dermatol

251

175

View full text Add to dashboard Cite

mentioning

confidence: 99%

Defining the Clinical Course of Metastatic Skin Cancer in Organ Transplant Recipients

Martinez

Otley²,

Stasko³

et al. 2003

Arch Dermatol

251

175

View full text Add to dashboard Cite

“…The incidence of SCC increases with the length of post-transplant followup, thereby supporting the argument that the development of SCC is associated with cumulative exposure to immunosuppressive agents [17]. SCC is an aggressive disease in transplant recipients [18,19]. Half of those who develop NMSC are likely to develop a second NMSC within 3.5 years, with men having a significantly higher risk for recurrence than women [14].…”

Section: Nmsc Epidemiologymentioning

confidence: 66%

Malignancy After Solid Organ Transplantation: An Overview

2008

View full text Add to dashboard Cite

Disclosure:This article discusses the use of acitretin (manufactured by Connetics) for prophylaxis of non-melanoma skin cancers; cyclophosphamide * (Bristol-Myers Squibb), adriamycin * (Pharmacia), prednisone * (Pfizer), vindesine (Lilly/EG Labo; not available in the U.S.), rituximab * (Genentech), and monoclonal anti-IL-6-antibody (multiple manufacturers) for post-transplant lymphoproliferative disorder (PTLD) (clinical trial); vincristine * (Lilly/Gensia Sicor) and bleomycin * (Bristol-Myers Squibb) for PTLD and Kaposi's sarcoma (KS); liposomal daunorubicin (Gilead) for KS (indicated for HIV-associated KS); paclitaxel (BristolMyers Squibb) for KS (indicated for AIDS-associated KS); imatinib (Novartis) and bevacizumab (Genentech) for KS; and matrix metalloproteinase inhibitor COL-3 (CollaGenex) for KS (clinical trial). ( * Drugs marked with asterisks are indicated for use in malignant lymphomas generally, but no specific mention is made of PTLD.)The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the authors, planners, independent peer reviewers, or staff managers. LEARNING OBJECTIVESAfter completing this course, the reader should be able to:1. Describe the most common malignancies encountered after solid organ transplantation.2. Discuss the pathogenesis of malignancy after solid organ transplantation. Administer standard treatment for common post-solid organ transplantation malignancies.This article is available for continuing medical education credit at CME.TheOncologist.com. CME CME ABSTRACT CASE PRESENTATIONA 49-year-old man with no prior medical history initially presented with severe dyspnea progressive over 6 months.The patient underwent an open-lung biopsy that confirmed the diagnosis of idiopathic pulmonary fibrosis. He was assessed for lung transplantation. An extensive pretransplant

show abstract

“…Among the organ transplant recipients the percentage of patients with an aggressive course of the disease is about 4.3% [35]. However, the high portion of such cases in these [1,4,24,33,34,35]. These reports mainly originate from the Australian continent.…”

Section: Discussionmentioning

confidence: 99%

The therapy of virus-associated epithelial tumors of the face and the lips in organ transplant recipients

Hyckel

Schleier

Meerbach

et al. 2003

Medical Microbiology and Immunology

View full text Add to dashboard Cite

The risk of developing malignant cutaneous neoplasms is increased after organ transplantation. We report three patients with malignant tumors of the epithelium of the facial skin and the lips after kidney and heart transplantation, respectively. They showed an aggressive course of the disease with more than five synchronous or metachronous basal cell and squamous cell carcinomas. Tissue samples were Epstein-Barr virus (EBV) positive by PCR. Using an in situ hybridization technique EBV-encoded RNA (EBER) was detected in tumor-infiltrating lymphocytes. The aggressive course was not alone controllable by surgical or radiological therapy. The systemic and topical application of cidofovir (Vistide) led to remarkable remissions, to a better confinement and operability of the tumors, and to a cessation of tumor pain. The photodynamic therapy represents another opportunity for managing superficial local recurrences and multiple tumors. In conclusion, the results of these case reports demonstrate that combined antiviral, photodynamic and surgical therapy may be used successfully to treat aggressive cutaneous malignancies in patients after organ transplantation.

show abstract

High Incidence and Clinical Course of Aggressive Skin Cancer in Heart Transplant Patients: A Single-Center Study

Cited by 74 publications

References 3 publications

Defining the Clinical Course of Metastatic Skin Cancer in Organ Transplant Recipients

Defining the Clinical Course of Metastatic Skin Cancer in Organ Transplant Recipients

Malignancy After Solid Organ Transplantation: An Overview

The therapy of virus-associated epithelial tumors of the face and the lips in organ transplant recipients

Contact Info

Product

Resources

About